Key result
Weight loss plus atenolol reduces 6-month cardiovascular risk ~17% from baseline in hypertensive patients.
Why the study?
The 6-month change in cardiovascular (coronary heart disease) risk as a function of alternative diet and drug regimens for mild hypertension needed to be evaluated.
Does diet and drug therapy reduce cardiovascular risk in patients with mild hypertension?
RCT (n=692)
Placebo-controlled
Stratified by clinical center and race into 9 diet plus drug combinations
Yes
Does diet and drug therapy reduce cardiovascular risk in patients with mild hypertension?
Answers are grounded in this paper and cite their sources.
Dietary therapy, particularly weight reduction, is an important adjunctive treatment to pharmacotherapy for reducing overall cardiovascular risk in patients with mild hypertension.
Objective To evaluate the 6-month change in cardiovascular (coronary heart disease) risk as a function of diet and drug therapy for mild hypertension. Design Collaborative randomized, controlled clinical trial to assess the efficacy of alternative regimens in treating mild hypertension. Setting Three university-based tertiary care centers-the Trial of Antihypertensive Interventions and Management (TAIM). Patients Six hundred and ninety-two men and women ages 21 to 65 years with diastolic blood pressure between 90 and 100 mm Hg and weight between 110% and 160% of ideal weight. Measurements and main results Patients stratified by clinical center and race were randomized into diet (usual, low sodium-high potassium, weight loss) and drug (placebo, chlorthalidone, and atenolol) groups resulting in nine diet plus drug combinations. The cardiovascular risk at 6-month follow-up was estimated relative to baseline in 692 participants using the Framingham Study model. Due to the blood pressure reduction, cardiovascular risk declined from baseline for all treatment groups (except the usual diet plus chlorthalidone group because of increased cholesterol levels). The relative cardiovascular risk at 6 months compared to baseline ranged from 0.83 in the weight loss plus atenolol subgroup to 1.03 in the usual diet plus chlorthalidone subgroup. The active drug plus weight loss groups showed the lowest relative cardiovascular risk at 6 months. Conclusions Mild hypertension was generally reduced to desirable levels within 6 months by monotherapy. Evaluating blood pressure changes together with the risk factors indicated a differential effect on overall cardiovascular risk depending on the diet and drug used. Dietary therapy, particularly weight reduction, was important adjunctive treatment in reducing overall cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Albert Oberman (1990) conducted an RCT in Mild hypertension (n=692). Diet (low sodium-high potassium or weight loss) and drug therapy (chlorthalidone or atenolol) vs. Usual diet and placebo was evaluated on 6-month relative cardiovascular (coronary heart disease) risk compared to baseline estimated using the Framingham Study model (RR 0.83 to 1.03 across subgroups). Diet and drug regimens altered 6-month relative cardiovascular risk from baseline, ranging from 0.83 with weight loss plus atenolol to 1.03 with usual diet plus chlorthalidone.
Synapse has enriched 10 related papers. Consider them for comparative context: